Investigational Long-Acting Injectable Cabotegravir Shows Superior Efficacy Over Daily Oral PrEP

July 13, 2020

ByJared Berberabe

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

Merck Announces New Trial Results for Islatravir Plus Doravirine in Antiretroviral-Naïve Adults With HIV-1

July 09, 2020

ByGabrielle Ientile, Assistant Editor

Both trial sub-analyses will be presented at the virtual 23rd International AIDS Conference.

Survey: Changes in PrEP Utilization, Risk Behaviors During COVID-19 Pandemic

July 08, 2020

ByJennifer Barrett

Survey results on PrEP access and utilization during COVID-19 shelter-in-place orders presented at the 23rd International AIDS Conference.

FDA Approves Fostemsavir for Heavily Pretreated Patients With HIV

July 03, 2020

ByJennifer Barrett

Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.

FDA Approves Dolutegravir Tablets for Oral Suspension for Children With HIV

June 12, 2020

Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.

Pharmacists Fight HIV

June 08, 2020

ByFrieda Wiley, PharmD

Virtual care takes center stage amid the pandemic.

HIV PrEP Uptake Remains Low Among Teens

May 20, 2020

ByMiranda Hester

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV. 

Study Finds Most Women With HIV Prefer LAI Antiretroviral Therapy Over Daily Pill

April 30, 2020

ByGabrielle Ientile, Assistant Editor

In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.

Study Findings Support Scaling Up PrEP Use in the US to Fight HIV

March 23, 2020

ByGabrielle Ientile, Assistant Editor

Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.

CROI 2020: New Data Comparing Descovy, Truvada for HIV PrEP

March 10, 2020

At the 2020 Conference on Retroviruses and Opportunistic Infections (CROI), longer-term study results on emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for HIV PrEP were presented.